AMAG Pharmaceuticals, Inc.
Merger
Overview
- Date:
- 10/1/2020
- Case Caption:
- Buss v. AMAG Pharmaceuticals, Inc., et al.
- Stock Symbol:
- AMAG
- Company Name - Buyer:
- Covis Group S.á. r.l.
- Status:
- Filed
- Merger Announcement Date:
- 10/1/2020
- Filing Date:
- 11/4/2020
- Court:
- U.S. District Court: Eastern New York
NEW YORK, October 2, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Covis Group S.á. r.l.
On October 1, 2020, AMAG announced that it had signed an agreement to be acquired by Covis Group for $498 million. Pursuant to the merger agreement, AMAG stockholders will receive $13.75 in cash for each share of AMAG common stock owned. The deal is scheduled to close in the fourth quarter of 2020.
Bragar Eagel & Squire is concerned that AMAG’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for AMAG’s stockholders.
Case Updates
Case Files
-
Buss v. AMAG Pharmaceuticals, Inc., et al.